samedan logo
 
 
 
spacer
home > ebr > autumn 2007 > a cee of opportunity
PUBLICATIONS
European Biopharmaceutical Review

A CEE of Opportunity

Bogdan Nietubyc of Hesperion Ltd asks how pharma companies, biotechs and CROs can improve their clinical outsourcing processes in the CEE region and Russia

It is very well known that an increasing number of patients in global clinical trials are being recruited in the Central and Eastern European (CEE) region, Russia and Commonwealth of Independent States (CIS) countries. In large multinational studies it is common that these countries are a few months ahead of patient recruitment schedules. Many US and Western companies are initiating rescue projects in CEE and Russia, to be put into practice if the patient recruitment of their ongoing US-based or Western European trials fail to meet the requirements. The list of factors influencing high recruitment performance in CEE and Russia is very long, and includes:

  • The wide availability of treatment-naďve patients
  • Lack or insufficient availability of preventive medicine
  • Shortage of available therapy, abundance of high quality investigational sites
  • Motivation of investigators (investigator fees still represent a significant income for the physicians)

MATTERS FOR CONCERN

Everything looks very promising, and from experience we know that it is indeed worthwhile being in the region. Yet are there really only advantages for sponsors and CROs planning to go to CEE countries and Russia? Certainly not – conducting clinical trials in this enormous region also has its downsides, such as: bureaucracy; local regulations differing from those we know well in Western countries; and very slow harmonisation or delays in the implementation of EU guidelines, even in the new CEE EU-member countries. Good clinical practice (GCP) and good manufacturing practice (GMP) standards, although officially adopted and respected, have to be controlled very carefully by locally-based monitors and auditors.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Bogdan Nietubyc qualified in Warsaw as a Veterinarian and later completed an MBA at the International Business School in Warsaw. He has extensive pharmaceutical industry experience, having spent eight years with Bristol-Meyers Squibb and four years in the largest Polish generic pharmaceutical company, Polpharma SA. Having joined Polpharma as Sales and Marketing Director and Member of the Board soon after the company’s privatisation, he was responsible for the commercial strategy and implementation of the new business model in Poland, as well as for the restructuring of the sales and marketing departments. Between 2002 and 2004 Bogdan lived in Moscow where he was responsible for starting up Polpharma business in the Russian federation and CIS countries. Before joining Hesperion permanently he worked as an independent consultant for BMS and Hesperion in Poland. Today, Bogdan is the Regional Director for Central and Eastern Europe and manages the Hesperion CEE office in Poland. He has also established a close collaboration with the newly opened Russian office in Moscow.
spacer
Bogdan Nietubyc
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline

Sanofi announced today an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments.
More info >>

White Papers

7 Common Myths about QP Training Debunked: A Guide for Senior Managers

RSSL

The role of the Qualified Person (QP) in the pharmaceutical industry is mandated by law (Directive 2001/83/EC, Directive 2001/20/EC, UK SI 2012/1916, UK SI 2004/103). Every holder of a relevant Manufacturers Authorisation (human and veterinary) must have at least one QP; without one, no batch of medicinal product can be certified for release for sale.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement